신세포암 개에서 toceranib 연관 손발바닥 홍반이상감각(PPES)

This case report describes a dog with high-grade renal cell carcinoma Revised February 19, 2026 Accepted March 5, 2026 that developed recurrent palmar-plantar erythrodysesthesia syndrome (PPES), hypopigmentation, and hyperkeratotic footpad lesions during adjuvant treat- *Correspondence: Hyeona Bae ment with toceranib phosphate. The patient exhibited dose-dependent dervetbha@gnu.ac.kr matological reactions and proteinuria, which repeatedly improved upon drug † SeJung An and Kyuri Kim contributed equally to withdrawal but recurred after reintroduction. Comprehensive dermatological this work. and systemic evaluations ruled out infectious or allergic etiologies, and adverse Funding This work was supported by the Korea events were graded using the Veterinary Cooperative Oncology Group Common Institute of Planning and Evaluation for TechTerminology Criteria for Adverse Events (VCOG-CTCAE) v2 criteria. The clinical nology in Food, Agriculture and Forestry (IPET) through the Agriculture and Food Convergence features closely resemble hand-foot skin reaction (HFSR), which has been widely Technologies Program for Research Manpower reported in human oncology with multitarget tyrosine kinase inhibitors (TKIs). development funded by the Ministry of Agriculture, Food and Rural Affairs (MAFRA) (grant Notably, dermatological toxicity was successfully controlled through dose-internumber: RS-2024- 00398561). val modification from every other day to every 3-4 days, without requiring permanent discontinuation of toceranib. This case highlights the underrecognized potential of TKI-associated cutaneous toxicity in dogs, supports the applicability of human National Cancer Institute’s CTCAE–based management strategies to veterinary patients, and underscores the need for evidence-based guidelines for monitoring and managing palmar-plantar erythrodysesthesia syndrome (PPES)/ hand-foot skin reaction (HFSR)-like reaction in canine oncology.